Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can
prevent HIV-1 infection in humanized mice and macaques when passively transferred. New …

In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV‐1
broadly neutralizing antibodies (bNA bs) did not display measurable binding to a …

Passive immunization with HIV-1–neutralizing monoclonal antibodies (mAbs) is being
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs …

Sexual transmission of HIV-1 is an inefficient process, with only one or few variants of the
donor quasispecies establishing the new infection. A critical, and as yet unresolved …

Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how
these antibodies develop remain important goals in the quest to rationally develop an HIV-1 …

Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

Broadly neutralizing antibodies (bNAbs) have been isolated from selected HIV-1-infected
individuals and shown to bind to conserved sites on the envelope glycoprotein (Env) …

A major goal for HIV-1 vaccine development is the production of an immunogen to mimic
native, functional HIV-1 envelope trimeric spikes (Env) on the virion surface. We lack a …

The development of a preventative HIV-1 vaccine remains a global public health priority.
This will likely require the elicitation of broadly neutralizing antibodies (bNAbs) able to block …

Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the
prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the …